Diffuse large B-cell lymphoma (DLBCL) is a lymphatic system cancer that seriously threatens human health and still faces great challenges in its effective management. Leveraging our pioneering efforts in DLBCL research, Protheragen is at the forefront of developing targeted therapies to enhance the precision treatment of DLBCL. We offer complete assistance tailored to fulfill your requirements regarding DLBCL drug development.
Diffuse large B-cell lymphoma (DLBCL) represents both the most prevalent and the most aggressive type of non-Hodgkin lymphoma. It is characterized by the proliferation of malignant B-cells which metastasize into lymph nodes, bone marrow, and various other organs. Even with therapies such as R-CHOP, there remains a 40% rate of relapse or refractory disease due to the cancer's molecular heterogeneity and resistance mechanisms.
Fig.1 The pathogenesis of EBV-associated diffuse large B-cell lymphoma (DLBCL). (Chabay, Paola., 2021)
Diffuse large B-cell lymphoma (DLBCL) is caused by the malignant transformation of mature B cells and it is fueled by the intricate factors of genetic changes, dysregulated signaling pathways, and environmental interactions. Key oncogenic events include recurrent mutations and translocations of genes such as MYC, BCL2, and BCL6 that disrupt normal cell cycle control and apoptosis. In addition, immune evasion through PD-L1 expression and tumor microenvironmental interactions further promote lymphomagenesis. Some cases are also associated with infection (e.g., EBV, HIV) or chronic inflammation.
Fig.1 Pathogenesis of B-cell non-Hodgkin lymphomas. (Klanova, Magdalena, and Pavel Klener., 2020)
The diffuse large B-cell lymphoma (DLBCL) market size reached USD 3,907.8 million in 2023. Looking ahead, the market size is expected to reach USD 5,257.7 million by 2034, growing at a CAGR of 2.7% during 2024-2034. The market is driven by advances in targeted therapies and personalized medicine.
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| TQB2825 Injection + Chemotherapy | TQB2825: Induces ADCC/CDC against B-cells. Chemotherapy: DNA damage and cell cycle disruption. |
CD20/DNA | NCT06854445 | Phase II |
| BTK Inhibitor | Blocks BCR signaling and NF-κB activation. | BTK | NCT01325701 | Phase II |
| Bendamustine + Rituximab | Induces DNA damage and ADCC/CDC against B-cells. | DNA/CD20 | NCT01234467 | Phase II |
| Glofitamab | Recruits T cells to tumor cells. | CD20 x CD3 | NCT06552572 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Recognizing the complexity of diagnosing and treating diffuse large B-cell lymphoma (DLBCL), Protheragen is committed to building a team of experts to provide cutting-edge diagnostic and therapeutic development solutions. Our commitment lies in providing a variety of customized therapy development services to meet the diverse research needs of our customers. We also excel in generating precise disease models that are carefully engineered to replicate the unique features of DLBCL. These models are valuable tools for validating the safety and efficacy of potential therapeutics.
At Protheragen, we are committed to validating and optimizing therapies for diffuse large B-cell lymphoma (DLBCL) through preclinical studies including pharmacodynamics (PD), pharmacokinetics (PK) and toxicology to ensure their successful regulatory approval. Should you require further details or quotations pertaining to the services we offer, feel free to get in touch with us.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
